曲美他嗪治疗稳定型劳力性心绞痛疗效观察被引量：3

下载PDF

导出

摘要目的观察曲美他嗪(TMZ)对稳定型劳力性心绞痛的疗效。方法31例稳定型劳力性心绞痛患者在常规治疗的基础上,加用TMZ治疗,12周后,观察治疗前后每周心绞痛发作次数、每周硝酸甘油片用量、收缩压心率乘积、运动诱发心绞痛所需时间、运动持续时间等。结果治疗后患者每周心绞痛发作次数(3.0±1.9)次,硝酸甘油片的用量(2.9±1.5)mg均明显减少(P<0.01);运动诱发心绞痛的所需时间(469.4±85.8)s,运动持续时间(641.3±121.6)s,均明显延长(P<0.05);而收综压与心率乘积仅轻度改变,前后比较无统计学意义(P>0.05)。结论TMZ具有抗心肌缺血作用,显著减少心绞痛患者硝酸甘油用量并提高运动耐量。

作者谢秀乐宋亚辉蔡伦安楚咏函张永庆

机构地区信阳市中心医院心内科

出处《医药论坛杂志》 2006年第24期87-88,共2页 Journal of Medical Forum

关键词曲关他嗪心绞痛运动试验

分类号 R972 [医药卫生—药品]

引文网络
相关文献

参考文献4

1张佩生,王赤京,张普,杨建峰,梁雪,陈永生,高瑜.不稳定性心绞痛的临床治疗[J].医药论坛杂志,2005,26(21):34-35. 被引量：2
2Kanton PF, Lueien A, Kozak R, et al. The antiamginal drug tnimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibitimg mitoehondrial long chain 3 - ketaeyl eoenzyme A thiolase [ J ]. Circ Res,2000,86 ( 5 ) : 580-588
3Allibandis. Effects of trimetazidine on metabolic and functional recovery of postischemic rathearts [ J ]. Cardiovasc Drugs Ther, 1998,12 (2) :543-548
4曲美他嗪Ⅳ期临床试验协作组.曲美他嗪治疗冠心病合并左心功能不全患者的疗效研究[J].中华心血管病杂志,2005,33(9):793-795. 被引量：123

二级参考文献11

1Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischemic cardiomyopathy. Eur Heart J Supplements,2001,3 ( Suppl 0) : 02-07.
2Kantor PF, Lucien A, Kozak R, et aL The anfianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000, 86:580-588.
3Renaud JF. Internal pH, Na^+ , and Ca^++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther,1988,1:677-686.
4Schiller NB, Shah PM, Crawford M, et aL Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional Echocardiograms. J Am Soc Echocardiogr, 1989, 2:358-367.
5Aussedat J, Ray A, Kay L, et aL Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol, 1993,21 :128-135.
6Brottier L, Baaxt JL, Combe C, et aL Therapeutic value of a cardioprotective agent in patients with severe isehemic cardiomyopathy. Eur Heart J, 1990, 11:207-212.
7Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J, 2001, 22:2164-2170.
8Cordon A, Culine S. Anonymous Adjusted - dose warfarin versus low- intensity, tixed- dose warfarin plus aspirin for high - risk patients with atrial fibrillation : srtoke prevrntion in atrial fibrllaion,Ⅲ randomized clinical trial, Lancet,1996,384:633.
9Toschi V, Gallo R, Lettino, et al. Tissues factor modulates the thrombogenicity of human atherosclerotlc plagues. Circnlation, 1997,95 (3) :594.
10Ruddock V, Meade TW. Factor Ⅶ activity and ischaemic heart disease: fatl and non - fatal events, QJM, 1994,87(7) :403.